GH Research (NASDAQ:GHRS) Trading Down 3.1%

GH Research PLC (NASDAQ:GHRS) fell 3.1% on Wednesday . The stock traded as low as $10.54 and last traded at $10.65. 11,876 shares changed hands during trading, a decline of 91% from the average session volume of 134,902 shares. The stock had previously closed at $10.99.

Analyst Ratings Changes

GHRS has been the topic of a number of analyst reports. JMP Securities lowered their target price on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Monday, March 4th.

GH Research Price Performance

The stock’s fifty day moving average is $9.66 and its two-hundred day moving average is $7.83.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Analysts expect that GH Research PLC will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in GH Research by 13,760.0% in the 4th quarter. Bank of America Corp DE now owns 2,772 shares of the company’s stock valued at $27,000 after buying an additional 2,752 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in GH Research by 246.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,075 shares of the company’s stock valued at $33,000 after buying an additional 2,898 shares during the last quarter. Northern Trust Corp purchased a new stake in GH Research in the 4th quarter valued at about $59,000. Renaissance Technologies LLC purchased a new stake in GH Research in the 1st quarter valued at about $86,000. Finally, State Street Corp purchased a new stake in GH Research in the 3rd quarter valued at about $127,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.